Dr. Hofmeister Discusses Sequencing Treatment in Myeloma

Craig Hofmeister, MD, associate professor, The Ohio State University Comprehensive Cancer Center, discusses sequencing treatment in multiple myeloma.

General upfront treatment for myeloma is a proteasome inhibitor, immunomodulatory drug (IMiD), dexamethasone, and then transplant. From there, based on the patient’s risk profile, it is a 1- to 3-drug maintenance regimen.

At the time of relapse, monoclonal antibodies are showing excellent response rates in combination. As for the third- and fourth-line settings, agents are currently being tested but are showing significant side effects, says Hofmeister.